Providence spun out its fourth digital health startup: Praia Health, a platform designed to build stronger relationships with patients by personalizing their healthcare journeys and connecting them to relevant resources and services. The startup also announced the closing of a $20 million Series A funding round led by Frist Cressey Ventures.
Forta Health raised $55 million in Series A funding on Wednesday. The startup offers a platform to help family caregivers quickly access care to manage their loved ones' chronic conditions. Its first area of focus is autism spectrum disorder (ASD).
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Ketryx raised $14 million in Series A funds. The startups sells a platform — designed around FDA regulations and quality standards — that automates much of the work required from medical device companies’ development and quality teams.
Bright Uro raised $23 million in Series A funds to help achieve FDA clearance for its urodynamics system and launch the product in the U.S. Should it be cleared, the system will become the first product on the market able perform urodynamic monitoring wirelessly and without a catheter, the company's CEO said.
Allara raised $10 million in a Series A funding round led by GV. The startup offers membership-based virtual services to treat women's chronic hormonal conditions, such as PCOS and endometriosis. CEO Rachel Blank — former executive at Ro and investor at General Catalyst — founded the company partly due to the difficulty she experienced arriving at her own PCOS diagnosis.
Bold, a Los Angeles-based company offering a healthy aging platform for older adults, closed a $17 million Series A funding round. The startup seeks to improve the health of Medicare Advantage beneficiaries through personalized exercise programs designed to prevent falls, decrease musculoskeletal pain and boost physical activity levels.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The startup intends to use the money to expand its sales team, enter new markets and increase the breadth of its product offering.
The startup's product, which is also called Hero, sorts and dispenses medication, automates refills and offers audible and digital reminders.
Aphelion Capital led the round for the Chicago-based startup, whose solution focuses on improving communication and coordination in the operating room.
Circulation, a Boston-based startup focused on the non-emergency medical transportation space, said it has raised $10.5 million from investors such as Boston Children's Hospital, Humana and Intermountain Healthcare Innovation Fund.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Targeting the growth factors that influence cell proliferation and differentiation in disease is a pretty “well-trodden” field, but Cambridge biotech Scholar Rock purports to take a new spin on the concept. It’s announced a $20 million Series A financing round, and plans to use the funds to move its preclinical work into clinical drug development. Scholar Rock is […]
Bronchopulmonary dysplasia is a common condition among premature infants that require ventilation after birth. It causes inflammation and scarring in their delicate lungs, leading to serious complications at the earliest and most critical stages of a preemie’s development. Cincinnati-based Airway Therapeutics has raised $4.6 million in Series A financing for its new treatment, AT-100, that prevents BPD in preemies. The company has developed a […]